以下任意一個(gè)標(biāo)準(zhǔn)號(hào)即可YBH05892018YBH07222020   [更多]

質(zhì)量標(biāo)準(zhǔn)/進(jìn)口注冊(cè)標(biāo)準(zhǔn)中需有對(duì)氨基酸和短肽類較為詳細(xì)的測(cè)定方法，不限劑型（最好有較詳細(xì)的色譜條件、對(duì)照品選擇及質(zhì)控限度）   [更多]

求購(gòu)磷酸西格列汀和磷酸西格列汀制劑最新的進(jìn)口注冊(cè)質(zhì)量信息   [更多]

求購(gòu)磷酸奧司他韋膠囊最新進(jìn)口質(zhì)量信息   [更多]

求購(gòu)復(fù)方聚乙二醇電解質(zhì)散藥品注冊(cè)質(zhì)量信息   [更多]

求購(gòu)衛(wèi)生部藥品標(biāo)準(zhǔn)中藥成方制劑第十二冊(cè)及藥典業(yè)發(fā)（1998）第109號(hào)文 低糖型的標(biāo)準(zhǔn)   [更多]

注射用六氟化硫微泡   [更多]

YBH，2018版   [更多]

2,6-二甲基苯胺作為基因毒性雜質(zhì)控制，它的每日最大攝入量是多少？（1.5μg/天做不到）目前找到一個(gè)雷諾嗪緩釋片在澳洲申報(bào)的資料中提到2,6-二甲基苯胺的每日最大攝入量范圍是20.4μg/天~110μg/天，有沒有哪位大神知道這兩個(gè)值的來源及推導(dǎo)過程，求助。原文如下：The sponsor also commissioned two nonclinical risk assessments on DMA relative to  potential exposure from ranolazine under the conditions of use. Both assessors referred to  methodologies advocated in the ICH guideline.21 The updated guideline permits the use of  compound-specific assessments (compared with. TTC-based acceptable intake of  1.5 μg/day) when sufficient carcinogenicity data exists, such that a compound-specific  acceptable intake can be extrapolated from measures of carcinogenic potency. Information  on the carcinogenicity of DMA is available from a 2 year dietary study in rats (NTP, 1990)  and is the only source of data on carcinogenic potency. The first nonclinical assessor referred to a follow-up report to the NTP report where  carcinogenic potential (TD50) was set at 20.4 mg/kg. By linear extrapolation the  acceptable lifetime daily intake was calculated as 0.41 μg/kg/day (24.5 μg/day for 60 kg  adult or 20.4 μg/day for 50 kg adult). The amount of DMA detected in 750 mg ranolazine  tablets after 24 months storage (1.6 μg/tablet or 3.2 μg/day based on average batch values  outlined above in Table 7) were at least 6.4 fold lower than the extrapolated acceptable  lifetime daily intake of 20.4 μg/day (for 50 kg adult at the MRHD). The assessor indicated  that this was an acceptable safety factor but recommended that the shelf life of Ranexa be  no more than 24 months to ensure ranolazine degradation was minimal. The second nonclinical assessor evaluated risk assessments conducted by other regulatory  bodies where acceptable daily levels of DMA ranged between 20.4 μg/day to 110 μg/day  (for 50 kg adult). The most conservative approach gave acceptable daily levels of  29 μg/day (20.4 μg/day for 50 kg adult) and was the same as that   [更多]

最新版，2017   [更多]